Metformin reduces the Walker-256 tumor development in obese-MSG rats via AMPK and FOXO3a
- 1 January 2015
- journal article
- research article
- Published by Elsevier in Life Sciences
- Vol. 121, 78-87
Abstract
No abstract availableKeywords
Funding Information
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (141127/2010-4)
- Fundação de Amparo à Pesquisa do Estado de São Paulo (2009/54886-4)
- FAPESP
- CNPq
- Instituto Nacional de Ciências e Tecnologia (INCT) of Obesity and Diabetes
This publication has 67 references indexed in Scilit:
- Metformin Therapy and Risk of Cancer in Patients with Type 2 Diabetes: Systematic ReviewPLOS ONE, 2013
- Molecular mechanism of action of metformin: old or new insights?Diabetologia, 2013
- A novel proteasome inhibitor acting in mitochondrial dysfunction, ER stress and ROS productionInvestigational New Drugs, 2012
- Akt, FoxO and regulation of apoptosisBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2011
- AMP‐activated Protein Kinase and FoxO Transcription Factors in Dietary Restriction–induced LongevityAnnals of the New York Academy of Sciences, 2009
- The Role of Obesity and Related Metabolic Disturbances in Cancers of the Colon, Prostate, and PancreasGastroenterology, 2007
- FoxOs Are Lineage-Restricted Redundant Tumor Suppressors and Regulate Endothelial Cell HomeostasisCell, 2007
- Adipocytokines: mediators linking adipose tissue, inflammation and immunityNature Reviews Immunology, 2006
- Overweight, obesity and cancer: epidemiological evidence and proposed mechanismsNature Reviews Cancer, 2004
- Insulin signalling and the regulation of glucose and lipid metabolismNature, 2001